CME / MOC
The following ASH Academy offerings have been developed by subject-matter experts to meet your continuing medical education (CME) and maintenance of certification (MOC) needs. These clinically-relevant educational resources in hematology support your continuous professional development by offering various types of credit.
out of 7 CME/MOC products listed
A New Era of Hematology/Oncology Management Considerations
This two-part, audio-guided online course presents practical, foundational information on biosimilars, while also addressing issues and barriers most commonly encountered in the clinical setting.
Experts define and present key didactic information to provide practical, foundational information on biosimilars
Part II: What Would You Do?
Learners interpret the foundational information about biosimilars through the evaluation of three case-based scenarios
Jeffrey Crawford, MD
Duke Cancer Center
Gary H. Lyman, MD
Fred Hutchinson Cancer Research Center, University of Washington
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
CML Interactive Cases: An Immersive Simulated Learning Experience
This educational activity will provide an opportunity to explore two different CML cases. Learners will navigate treatment decisions based on patient presentation, history, and other findings that may impact the therapeutic approach.
This case explores risk assessment and initial treatment approach, monitoring treatment response, managing side effects, long-term therapy, and the potential for treatment-free remission.
This case explores possible reasons for treatment failure, monitoring and optimizing treatment adherence, monitoring treatment response and side effects, and multiple lines of therapy based on treatment history and risk.
Jessica Altman, MD
Elizabeth Hexner, MD, MS
University of Pennsylvania
Jorge Cortes, MD
MD Anderson Cancer Center
Kendra Sweet, MD
Moffitt Cancer Center
MDS+AML MATTER Program
The goals of this set of simulated patient cases are to provide guidance to the interdisciplinary team caring for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) on:
- The optimal diagnosis and classification of both MDS and AML
- Risk stratification and individualized treatment selection
- Assessment of treatment responses
- Monitoring for and mitigation of adverse events, and
- Patient education regarding prognosis and treatment choices
These activities are supported by an independent medical education grant from Celgene.
Robert Paul Hasserjian, MD
Massachusetts General Hospital
Harvard Medical School
Kirsten Roblee, BSN, RN, OCN
The James Cancer Hospital and Solove Research Institute
B. Douglas Smith, MD
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine